Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
grade F 1.28 -1.54% -0.02
PDSB closed down 1.54 percent on Wednesday, February 26, 2020, on 1.66 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical PDSB trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -1.54%
New 52 Week Low Weakness -1.54%
Outside Day Range Expansion -1.54%
Wide Bands Range Expansion -1.54%
Oversold Stochastic Weakness -1.54%
New 52 Week Closing Low Bearish -1.54%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Medicine Cancer Clinical Medicine Immunotherapy Oncology Cancers Prostate Cancer Breast Cancer Cancer Immunotherapy Melanoma Immunotherapies Head And Neck Cancer Oncolytics Biotech Cervical Cancer Anal Cancer Treatment Of Melanoma

Is PDSB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.754
52 Week Low 1.28
Average Volume 111,304
200-Day Moving Average 4.30
50-Day Moving Average 2.29
20-Day Moving Average 1.86
10-Day Moving Average 1.33
Average True Range 0.21
ADX 30.1
+DI 12.25
-DI 28.27
Chandelier Exit (Long, 3 ATRs ) 2.37
Chandelier Exit (Short, 3 ATRs ) 1.92
Upper Bollinger Band 2.99
Lower Bollinger Band 0.73
Percent B (%b) 0.24
BandWidth 121.10
MACD Line -0.35
MACD Signal Line -0.30
MACD Histogram -0.0428
Fundamentals Value
Market Cap 39.49 Million
Num Shares 30.9 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 0.00
Price-to-Book 3.94
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.37
Resistance 3 (R3) 1.38 1.36 1.36
Resistance 2 (R2) 1.36 1.34 1.36 1.35
Resistance 1 (R1) 1.32 1.32 1.31 1.31 1.34
Pivot Point 1.30 1.30 1.30 1.30 1.30
Support 1 (S1) 1.26 1.28 1.25 1.25 1.22
Support 2 (S2) 1.24 1.26 1.24 1.21
Support 3 (S3) 1.20 1.24 1.21
Support 4 (S4) 1.19